The Alberta Real World Evidence (RWE) Consortium
Alberta has one of the largest, most mature, detailed and comprehensive health system data depositories in Canada. As such, Alberta is poised to become a global leader in Real World Evidence (RWE) generation.
The Alberta RWE Consortium is the preferred first point of contact for RWE projects in Alberta. The Consortium engages key provincial stakeholders involved in RWE generation and utilization in order to advance provincial capabilities, ensure high quality projects managed to timelines and budget, and (where capacity is limiting) help focus projects and provincial resources on joint priorities between sponsors and the province.
Functions of the Consortium
Through the Consortium, industry and other health system partners have access to coordinated resources, expertise, and well-defined processes that ensures high-quality RWE studies.
Key functions of the Consortium include:
- Optimization of Alberta’s RWE studies
- Strengthening the Alberta RWE ecosystem
- Providing world class project support services, including study design, execution, and knowledge sharing
- Identifying and supporting projects that align with provincial health and policy priorities, ensuring relevance to decision-makers in Alberta
- Convening the best pan-provincial teams for commissioned, large-scale projects that may also have implementation components
The Consortium is primarily concerned with projects that are evaluations of safety, effectiveness, and/or value of a technology or other intervention that is currently used in clinical practice (i.e., not an intervention being tested in a randomized controlled trial in a limited patient population).
The Consortium is pleased to announce that the first project that will be supported by the Consortium is on the topic of biologics/biosimilars. The deliverables of this project will support Alberta Health with managing the translation, implementation, and monitoring of policy developed via a collaborative pan-Canadian process managed by the pan-Canadian Pharmaceutical Alliance (pCPA). The project will enable Alberta to realize the expected benefits from the introduction of biosimilars to the health system and the patients it serves. Click here to learn more.
Further information about the Alberta RWE Consortium can be found here: https://albertarwe.ca/about-us/.
The Consortium is co-chaired by the Director, Health Technology Assessment Unit of the University of Calgary, the Assistant Dean, Health Outcomes of the University of Alberta, and the Executive Director and CEO of the Institute of Health Economics. Additional organizations that are members of the Consortium include the Government of Alberta (the Ministry of Health and the Ministry of Economic Development and Trade), Alberta Health Services, and Alberta Innovates.
Contact the Consortium
The Institute of Health Economics is the Secretariat for the Consortium, and preferred first point of contact for industry and other sponsors interested in discussing a potential RWE project in the province. For more information about the Alberta RWE Consortium, please email us at firstname.lastname@example.org.